Acute Myeloid Leukemia Clinical Trial
Official title:
Phase-II Study Evaluating Midostaurin in Induction, Consolidation and Maintenance Therapy Also After Allogeneic Blood Stem Cell Transplantation in Patients With Newly Diagnosed Acute Myeloid Leukemia Exhibiting a FLT3 Internal Tandem Duplication
Verified date | June 2020 |
Source | University of Ulm |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase II, single-arm, open-label, multi-center study in adult patients with Acute
Myeloid Leukemia (AML) and FLT3-ITD as defined in inclusion/exclusion criteria.
The primary efficacy object is to evaluate the impact of midostaurin given in combination
with intensive induction, consolidation including allogeneic hematopoietic stem cell
transplantation and single agent maintenance therapy on event-free survival (EFS) in adult
patients with AML exhibiting a FLT3-ITD.
Sample size: 440 patients
The treatment duration of an individual patient is between 18 and 24 months. Duration of the
study for an individual patient including treatment (induction, consolidation [chemotherapy
or allogeneic SCT], maintenance and follow-up period: Maximum 8 years
Status | Completed |
Enrollment | 451 |
Est. completion date | February 26, 2020 |
Est. primary completion date | February 26, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients with suspected diagnosis of AML or related precursor neoplasm, or acute leukemia of ambiguous lineage (classified according to the World Health Organization (WHO) 2008 classification) - Presence of FLT3-ITD assessed in the central AMLSG reference laboratories - Patients considered eligible for intensive chemotherapy - WHO performance status of = 2 - Age = 18 years and = 70 years - No prior chemotherapy for leukemia except hydroxyurea to control hyperleukocytosis (= 7 days) - Non-pregnant and non-nursing. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL within 72 hours prior to registration ("Women of childbearing potential" is defined as a sexually active mature woman who has not undergone a hysterectomy or who has had menses at any time in the preceding 24 consecutive months) - Female patients in the reproductive age and male patients must agree to avoid getting pregnant or to father a child while on therapy and for 5 months after the last dose of chemotherapy - Women of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy). Hormonal contraception is an inadequate method of birth control - Men must use a latex condom during any sexual contact with women of childbearing potential, even if they have undergone a successful vasectomy (while on therapy and for 5 months after the last dose of chemotherapy) - Signed written informed consent. Exclusion Criteria: •AML with the following recurrent genetic abnormalities (according to WHO 2008): AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 AML with t(15;17)(q22;q12); PML-RARA (or variant translocations with other RARA gene fusions) - Performance status WHO >2 - Patients with ejection fraction < 50% by MUGA or ECHO scan within 14 days of day 1 - Organ insufficiency (creatinine >1.5x upper normal serum level; bilirubin, AST or ALP >2.5x upper normal serum level, not attributable to AML; heart failure NYHA III/IV; severe obstructive or restrictive ventilation disorder) - Uncontrolled infection - Severe neurological or psychiatric disorder interfering with ability of giving an informed consent - Patients with a "currently active" second malignancy other than non-melanoma skin cancers. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse within one year - Known positive for HIV; active HBV, HCV, or Hepatitis A infection - Bleeding disorder independent of leukemia - No consent for registration, storage and processing of the individual disease-characteristics and course as well as information of the family physician and/or other physicians involved in the treatment of the patient about study participation. - No consent for biobanking. |
Country | Name | City | State |
---|---|---|---|
Austria | Medizinische Universität Innsbruck | Innsbruck | |
Austria | Krankenhaus der Barmherzigen Schwestern Linz | Linz | |
Austria | Krankenhaus der Elisabethinen Linz GmbH | Linz | |
Austria | Universitätsklinik für Innere Medizin III Salzburg | Salzburg | |
Austria | Hanuschkrankenhaus Wien | Wien | |
Germany | Helios Klinikum Bad Saarow | Bad Saarow | |
Germany | Charité Universitätsmedizin Berlin | Berlin | |
Germany | Vivantes Klinikum Neukölln | Berlin | |
Germany | Marienhospital Bochum-Herne | Bochum | |
Germany | Medizinische Universitätsklinik Bochum | Bochum | |
Germany | Universitätsklinikum Bonn | Bonn | |
Germany | Städtisches Klinikum Braunschweig gGmbH | Braunschweig | |
Germany | Klinikum Bremen-Mitte gGmbH | Bremen | |
Germany | Klinikum Darmstadt | Darmstadt | |
Germany | Universitätsklinkum Düsseldorf | Düsseldorf | |
Germany | Kliniken Essen-Süd | Essen | |
Germany | Klinik für Onkologie, Gastroenterologie und Allg. Innere Medizin Esslingen | Esslingen | |
Germany | Malteser Krankenhaus St. Franziskus Hospital Flensburg | Flensburg | |
Germany | Medizinische Universitätsklinik Freiburg | Freiburg | |
Germany | MVZ Osthessen | Fulda | |
Germany | Klinik der Justus-Liebig-Universität Gießen | Gießen | |
Germany | Wilhelm-Anton-Hospital gGmbH Goch | Goch | |
Germany | Universitätsmedizin Göttingen | Göttingen | |
Germany | Asklepios Klinik Altona | Hamburg | |
Germany | Universitätsklinikum Eppendorf | Hamburg | |
Germany | Evangelisches Krankenhaus Hamm | Hamm | |
Germany | Klinikum Region Hannover GmbH | Hannover | |
Germany | Medizinische Hochschule Hannover | Hannover | |
Germany | SLK Kliniken Heilbronn GmbH | Heilbronn | |
Germany | Universitätskliniken des Saarlandes | Homburg/Saar | |
Germany | Städtisches Klinikum Karlsruhe | Karlsruhe | |
Germany | Städtisches Krankenhaus Kiel GmbH | Kiel | |
Germany | Caritas Krankenhaus Lebach | Lebach | |
Germany | Klinikum Lippe-Lemgo | Lemgo | |
Germany | Märkische Kliniken GmbH Lüdenscheid | Lüdenscheid | |
Germany | Universitätsklinikum der Otto-von-Guericke Universität Magdeburg | Magdeburg | |
Germany | Universitätsklinikum der Johannes Gutenberg-Universität Mainz | Mainz | |
Germany | Johannes Wesling Klinikum Minden | Minden | |
Germany | Klinikum rechts der Isar der TU München | München | |
Germany | Klinikum Schwabing | München | |
Germany | Stauferklinikum Mutlangen | Mutlangen | |
Germany | Ortenau Klinikum | Offenburg | |
Germany | Klinikum Oldenburg | Oldenburg | |
Germany | Pius Hospital Oldenburg | Oldenburg | |
Germany | Klinikum Passau | Passau | |
Germany | Universitätsklinikum Regensburg | Regensburg | |
Germany | Caritasklinik St. Theresia Saarbrücken | Saarbrücken | |
Germany | Diakonie-Klinikum Stuttgart | Stuttgart | |
Germany | Klinikum Stuttgart | Stuttgart | |
Germany | Klinikum Mutterhaus der Borromäerinnen gGmbH Trier | Trier | |
Germany | Krankenhaus der Barmherzigen Brüder Trier | Trier | |
Germany | Medizinische Universitätsklinik Tübingen | Tübingen | |
Germany | University Hospital of Ulm | Ulm | |
Germany | Schwarzwald-Baar Klinikum Villingen-Schwenningen | Villingen-Schwenningen | |
Germany | Helios Klinikum Wuppertal | Wuppertal |
Lead Sponsor | Collaborator |
---|---|
University of Ulm | Novartis Pharmaceuticals |
Austria, Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Event-free Survival | To perform two predefined subgroup analyses in the age-groups 18-60 years and 61-70 years evaluating the impact of midostaurin given in combination with intensive induction, consolidation including allogeneic hematopoietic stem cell transplantation and single agent maintenance therapy on event-free survival (EFS) in adult patients with AML exhibiting a FLT3-ITD. | 8years | |
Secondary | Rate of complete remission (CR) | Two months | ||
Secondary | Relapse-free survival | 8 years | ||
Secondary | overall survival | 8 years | ||
Secondary | Cumulative incidence of relapse | 8 years | ||
Secondary | cumulative incidence of death in CR | 8 years | ||
Secondary | Target (FLT3) inhibition by measuring the FLT3 plasma inhibitory activity | Evaluation of target (FLT3) inhibition by continuous dosing of midostaurin | 8 years | |
Secondary | Quality of life | Quality of life assessed by the EORTC Quality of Life Core Questionnaire (QLQ-C30), supplemented by information on self-assessed concomitant diseases, late treatment effects, and demographics initially, in first CR, after one year,3 and 5 years after initial diagnosis. | 5 years | |
Secondary | Rate of early deaths and hypoplastic deaths (ED/HD) | two months | ||
Secondary | Death in CR | 8 years | ||
Secondary | Toxicities | Type, frequency, severity (graded using the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] Version 3.0), timing and relatedness of hematological and non-hematological toxicities observed during the different treatment cycles | between 18 and 24 months | |
Secondary | Impact of allogeneic HSCT | Assessment of the relative impact of allogeneic HSCT analyzed as time-dependent variable on survival endpoints. | 8 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |